December 18, 2015
Managerial changes for Parabolic Drugs Limited
Indian pharmaceutical company Parabolic Drugs Limited has made certain changes to its board of directors. Namely, the company announced on…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 17, 2015
Bristol’s drug pricing under fire as UK agency rejects Opdivo
Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog.
December 17, 2015
Lilly’s and Boehringer Ingelheim’s insuline injection gets FDA’s nod
Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) were granted approval by the U.S. Food and Drug Administration (FDA) for Basaglar (insulin glargine injection) 100 units/mL.
December 16, 2015
AstraZeneca divests Entocort US rights to Perrigo for $380M
AstraZeneca has completed its agreement with Perrigo Company plc for the divestment of US rights to Entocort.
December 16, 2015
Lilly welcomes new board member
Eli Lilly and Company has elected Juan R. Luciano as a new member of its board, effective February 1, 2016.
December 15, 2015
BMS and UCLA conjoin oncology research program
Bristol-Myers Squibb has entered into a collaboration agreement with UCLA as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S.
December 15, 2015
Allergan’s IBS-D treatment Viberzi can be now prescribed in U.S.
Allergan has announced today that its first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D) – Viberzi – is now available by prescription in the U.S.
December 14, 2015
AstraZeneca in talks to buy cancer drugmaker Acerta for $5 billion – WSJ
British drugmaker AstraZeneca Plc is in advanced talks to buy privately held cancer drug developer Acerta Pharma BV for more than $5 billion (£3.3 billion).
December 14, 2015
JnJ, Verily in formation of Verb Surgical Inc.
Johnson & Johnson Monday announced the formation of Verb Surgical Inc., an independent surgical solutions company, in collaboration with Verily Life Sciences…
December 14, 2015
Horizon buys Crealta Holdings for $510M
Horizon Pharma plc has entered a definitive agreement to acquire Crealta Holdings LLC for $510 million in cash.